FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like Biotech Vets Launch With $38 Million and Will be Helmed By Biogen Alum February 26, 2017 FDA Calls Novartis' Melanoma Combo Drug a Breakthrough October 22, 2017 PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment January 10, 2018
